Fennec Pharmaceuticals Inc., of Research Triangle Park, N.C., completed its previously disclosed underwritten public offering of about 2.3 million common shares at $8.50 each. The firm also issued an additional 135,670 common shares in connection with the partial exercise of the underwriters' overallotment option. The total gross proceeds from the offering (before deducting the underwriting discounts and offering expenses) was about $21.1 million. Wedbush Pacgrow acted as the sole book-running manager for the offering. H.C. Wainwright & Co. served as the co-manager.